tirzepatide for sleep apnea fda approval The has expanded the of Eli Lilly's obesity medication Zepbound to include treating moderate to severe obstructive people with obesity — the first medication approved for the FDA approves weight-loss drug for

But some symptoms need medical attention

When lunch digests at a measured pace, the midafternoon slump softens

That's why at Klinic, Brunswick residents searching for Ozempic will find that we do not prescribe it

Abstract Background Recent reports of individuals experiencing suicidal and/or self-injurious behaviors while using liraglutide and semaglutide have heightened the concerns regarding neuropsychiatric safety of Glucagon-like peptide-1 agonists (GLP-1RAs)

Who GLP-1 weight loss is for - and who it isn't Patients we typically work with on GLP-1 weight management: Adults with BMI 30+ (obesity) who have not achieved sustained weight loss with lifestyle change alone Adults with BMI 27+ and weight-related comorbidities - type 2 diabetes, hypertension, dyslipidemia, sleep apnea, prediabetes, fatty liver disease Patients with insulin resistance or metabolic syndrome where the metabolic and weight pictures are intertwined Patients post-bariatric surgery with weight regain, where appropriate and coordinated with their surgical team GLP-1 medications are not appropriate for patients with personal or family history of medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, severe gastroparesis, or active eating disorders

Notably, GLP-1R agonists inhibit cancer progression in some malignant tumors [37,38,39,40]